Oncimmune Holdings, a Nottingham cancer detection firm, has acquired Protagen Diagnostics AG for up to £4.11million.
Protagen has an established revenue-generating business developing precision medicine and patient stratification tools for pharmaceutical multinationals in both immuno-oncology and autoimmune disease.
These tools support drug development, improve treatment strategies and patient management.
Dr Adam M Hill, CEO of Oncimmune said: “The acquisition of Protagen will accelerate Oncimmune’s product discovery process, will grow our library of known and novel immunogenic proteins, and will underpin the group’s ability to deliver value through the development of complementary diagnostics, a key component of our three-year forward strategy.
“Protagen’s biomarker discovery expertise and high throughput antigen screening technology are all highly synergistic to Oncimmune’s current capabilities. I look forward to working with our new colleagues to grow our company.”